Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LB Pharmaceuticals Inc (LBRX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission, alongside AI-assisted summaries to help interpret the information. As a clinical-stage biopharmaceutical company focused on schizophrenia, bipolar depression, and other neuropsychiatric diseases, LB Pharmaceuticals uses SEC filings to report on its financial condition, clinical development plans, corporate governance, and material agreements.
Core documents for LBRX include its registration statement on Form S-1/A, which describes the company’s business, risk factors, and the role of its lead product candidate, LB-102. This filing outlines LB-102’s status as a Phase 3–ready oral, small-molecule drug and a methylated derivative of amisulpride, and explains the company’s focus on neuropsychiatric indications such as acute schizophrenia and bipolar depression. Periodic reports and earnings-related Form 8-K filings provide condensed balance sheets, statements of operations, and narrative updates on research and development and general and administrative expenses.
Other current reports on Form 8-K document material corporate events, including lease amendments for additional office space, appointments of senior executives, and press releases announcing quarterly financial results. These filings also confirm that LB Pharmaceuticals’ common stock is listed on The Nasdaq Stock Market LLC under the ticker LBRX and that the company is incorporated in Delaware.
On Stock Titan, users can review these filings in chronological order and use AI-powered summaries to quickly understand key points from lengthy documents, such as the implications of clinical trial disclosures, changes in operating expenses, or the significance of material agreements. Access to insider transaction reports on Form 4, annual reports on Form 10-K, and quarterly reports on Form 10-Q, when filed, can further support analysis of LBRX’s progress as a clinical-stage biopharmaceutical issuer.
Marc L. Panoff, Senior Vice President, Finance and director of LB Pharmaceuticals (LBRX), filed an Initial Statement of Beneficial Ownership reporting direct ownership of 10,242 shares of common stock and multiple employee stock options. The filing lists options exercisable between 2028 and 2034 covering 27,609 underlying shares with exercise prices ranging from $41.84 to $69.72. The form is signed and dated 09/10/2025.
Pontifax entities and two individual managing partners report ownership of 1,411,681 shares of LB Pharmaceuticals Inc. common stock, representing 6.3% of the outstanding shares. The holdings arise from a prior $15,000,000 purchase of Series C preferred stock that converted into 411,681 common shares upon the issuer's IPO, plus additional purchases by Pontifax (Cayman) and Pontifax (Israel) of 363,737 and 626,263 common shares, respectively, in the IPO at $15.00 per share. The reporting group states the securities were acquired for investment purposes and may review, discuss or transact in the securities over time. One Reporting Person, Ran Nussbaum, serves on the issuer's board and may influence corporate matters. The filing otherwise discloses no recent transactions in the past 60 days and no relevant legal proceedings.
RA Capital and affiliated persons reported ownership of 1,675,000 shares, representing 7.5% of LB PHARMACEUTICALS INC (ticker LBRX) common stock as of September 12, 2025. The holdings are reported across RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals, Peter Kolchinsky and Rajeev Shah, each shown with shared voting and dispositive power over the 1,675,000 shares and no sole voting or dispositive power. The filing states the Fund holds the shares directly, RA Capital serves as the Fund’s investment adviser with delegated voting and disposition authority, and the Reporting Persons expressly disclaim that they form a "group." The 7.5% figure is calculated using 22,442,989 shares outstanding disclosed in the issuer’s September 10, 2025 prospectus.
Deep Track entities disclosed a meaningful ownership position in LB Pharmaceuticals Inc. Collectively the reporting persons hold 3,352,804 shares, representing 14.9% of common stock outstanding after the IPO (22,442,989 shares outstanding). DTBMF previously paid $25,000,000 for Series C preferred that converted into 686,138 common shares, and on September 12, 2025 DTBMF and DTSOF purchased 2,000,000 and 666,666 IPO shares, respectively, at $15.00 per share. A Deep Track affiliate, Rebecca Luse, serves on the Issuer's board, and the Reporting Persons state their holdings were acquired for investment purposes while reserving the right to review or change their position.
TCG Crossover II and affiliated parties report a passive >5% stake in LB Pharmaceuticals Inc. This Schedule 13G shows that TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and individual Chen Yu collectively beneficially own 1,745,015 shares, representing 7.8% of LB Pharmaceuticals' common stock based on 22,442,989 shares outstanding as stated in the issuer's prospectus.
The filing identifies shared voting and dispositive power for the reported shares and expressly disclaims an intent to influence control of the issuer. The reporting parties certify the holdings are not intended to change or affect control and provide the reporting entities' and representative's addresses and organizational details.
Commodore Capital entities and two individuals report beneficial ownership of 1,225,000 shares of LB Pharmaceuticals Inc. common stock, representing 5.5% of the outstanding shares based on 22,442,989 shares reported as issued and outstanding. The filing states the Firm (Commodore Capital LP) acts as investment manager to Commodore Capital Master LP and that the Firm's managing partners, Michael Kramarz and Robert Egen Atkinson, exercise investment discretion with respect to these securities. The ownership is reported as shared voting and dispositive power for each filer. A joint filing agreement is attached.
Deep Track reporting persons disclosed multiple transactions in LB PHARMACEUTICALS INC (LBRX) dated 09/12/2025. Series C preferred shares converted immediately prior to the issuer's IPO, producing common stock on a conversion ratio tied to the IPO price. Deep Track Biotechnology Master Fund, Ltd. reported receipt of 686,138 common shares from conversion. The reporting persons also acquired 2,000,000 common shares and 666,666 common shares by purchase at $15.00 per share. After these transactions, Deep Track Biotechnology Master Fund, Ltd. beneficially owned 2,686,138 shares directly and Deep Track Special Opportunities Fund, LP held 666,666 shares indirectly.
Deep Track Special Opportunities Fund, LP reported an initial Form 3 disclosing direct ownership of 666,666 shares of LB Pharmaceuticals Inc. (LBRX). The filing states the reporting entity is managed by Deep Track Capital, LP and that David Kroin, as managing member of the investment manager, may be deemed a beneficial owner of those shares. Affiliates of the reporting person, including Deep Track Biotechnology Master Fund, Ltd and Deep Track Capital, LP, separately filed Section 16 reports and collectively beneficially own in the aggregate more than ten percent of LBRX common stock.
Pontifax Management 4 G.P. (2015) Ltd. reported purchases and conversions of LB Pharmaceuticals Inc. securities on 09/12/2025. The filing shows an automatic conversion of 10,000,000 shares of Series C preferred stock into common stock immediately prior to the issuer's IPO closing, and the reporting person acquired 411,681 shares of common stock via conversion. In a separate transaction the reporting person purchased 1,000,000 shares of common stock at $15.00 per share, bringing total beneficial ownership reported to 1,411,681 shares on an indirect basis through affiliated Pontifax entities. The form is signed by the issuer's CFO on 09/16/2025.
Ran Nussbaum, a director associated with Pontifax entities, reported acquisitions of LB Pharmaceuticals (LBRX) securities on 09/12/2025. The filing shows an automatic conversion of Series C redeemable convertible preferred stock into common stock and a purchase of common shares. Specifically, 10,000,000 shares of Series C preferred were converted immediately prior to the companys IPO closing, and 1,000,000 common shares were acquired at $15.00 per share. After these transactions, the reporting person (through Pontifax-related entities) beneficially owned 1,411,681 common shares, held indirectly. The filing identifies Pontifax (Israel) VI LP and Pontifax (Cayman) VI LP as holders of the underlying securities and notes shared voting and investment power through Pontifax management.